Nanotech Investing Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nanotech Investing Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Nanotech Investing Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
Nanotech Investing NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
Nanotech Investing Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
nanotech investing Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
nanotech investing Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
